ARTICLE · 06 OCTOBER 2026
The Next Clinical Trial Compliance Frontier: Participant Support
Ankura's latest insights explore critical challenges across freight logistics, clinical trial compliance, cryptocurrency enforcement, parcel shipping costs, sanctions relief risks, cybersecurity threats, mortgage industry pressures, healthcare labor shortages, AI governance, and financial transformation. How are organizations navigating these complex operational, regulatory, and strategic landscapes in 2026?
United StatesLitigation, Mediation & Arbitration
An Advisory Perspective for Clinical Research Leadership
A cancer patient who lives 238 miles from the nearest research site should not have to choose between a promising clinical trial and the cost of getting there. Yet under today’s federal fraud and abuse rules, a sponsor who offers to cover that travel cannot be certain the gesture is lawful. That uncertainty is the problem the American Cancer Society Cancer Action Network (ACS CAN) and more than 100 patient advocacy and professional organizations have now asked the government to fix.
Their vehicle is an August 24, 2026 comment letter1 responding to a Request for Information (RFI) issued by the Department of Health and Human Services Office of Inspector General (HHS OIG) on June 24, 2026.2 The RFI was issued as part of Operation TrialBlazer, HHS’s broader push to restore U.S. leadership in clinical research.3 It asks a deceptively simple question: Should the Anti-Kickback Statute (AKS) and the Beneficiary Inducements Civil
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
View source
